Stocks
Zentalis Pharmaceuticals, Inc.ZNTL
NASDAQHealthcareBiotechnology$2.29
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing small molecule therapeutics for oncology, with a lead candidate targeting WEE1 kinase in solid tumors. Its pipeline includes ZN-c3, currently in Phase 2 trials for ovarian and uterine cancers, and ZN-d5, a BCL-2 inhibitor for hematologic malignancies. Investors track ZNTL for its potential in DNA damage response pathways and recent clinical data readouts.
52W Range: $1.21-$6.95
Congressional Interest in Zentalis Pharmaceuticals, Inc. (ZNTL)
No congressional trades have been disclosed for Zentalis Pharmaceuticals, Inc. (ZNTL) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ZNTL?
No congressional trades found for this stock.